Grifols (NASDAQ:GRFS) Stock Jumps 7.2% – What’s Next?

Grifols, S.A. (NASDAQ:GRFS) was up 7.2% during mid-day trading on Monday. The stock traded as high as $8.01 and last traded at $8.1050. 192,511 shares changed hands during trading, a decline of 70% from the average session volume of 636,375 shares. The stock had previously closed at $7.56.

Analyst Ratings Changes

Several analysts recently commented on GRFS shares. JPMorgan Chase & Co. lowered their target price on Grifols from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Monday. Weiss Ratings upgraded Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $9.00.

Grifols Stock Performance

The stock has a market cap of $5.38 billion, a P/E ratio of 41.55, a PEG ratio of 0.28 and a beta of 0.70. The company has a fifty day moving average of $7.58 and a 200 day moving average of $7.71. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.37 and a quick ratio of 0.81.

Institutional Trading of Grifols

Hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC boosted its position in shares of Grifols by 68.7% during the 3rd quarter. Signaturefd LLC now owns 4,372 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 1,781 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Grifols by 41.1% in the 3rd quarter. GAMMA Investing LLC now owns 6,588 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,918 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of Grifols by 36.0% in the 2nd quarter. Versant Capital Management Inc now owns 6,958 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,842 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Grifols by 50.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,961 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 2,998 shares in the last quarter. Finally, Financial Symmetry Inc bought a new stake in shares of Grifols in the 3rd quarter worth approximately $73,000.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.